For patients over 65 and in good health, this is a study to determine if a stem cell transplant combined with maintenance therapy is a better option than non-transplant chemotherapy approaches and if it will provide older patients longer remission rates, more time without symptoms, toxicity and therapy, and an improved quality of life. Although several groups have confirmed the feasibility of autologous transplantation in myeloma patients over 65 years of age, the literature related to autotransplantation in this age group remains scarce. Most of the literature related to myeloma treatment in patients over 65 years of age involves non-transplant chemotherapy regimens, so this study will compare the autologous transplant with maintenance therapy compared to non-transplant treatment options for that age group. Study Phase: Phase II Location: University of Iowa For More Information contact Annick Tricot at firstname.lastname@example.org
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.